|
WO2010148117A1
|
|
Therapeutic and diagnostic affinity purified specific polyclonal antibodies
|
|
US2009047686A1
|
|
Methods for identifying and producing specific amino acid dependent antibodies and uses thereof
|
|
WO2009005968A1
|
|
Assays for detecting antibodies to therapeutics
|
|
WO2007127308A2
|
|
Methods and devices for measuring sample coagulation
|
|
US2007098726A1
|
|
Methods of making and using antibodies directed to parathyroid hormone
|
|
EP1909833A2
|
|
Methods and devices for removing pathogens and detrimental substances from bodily fluids
|
|
US2006035282A1
|
|
Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
|
|
US2005170443A1
|
|
Methods and use of binding components for improving assay specificity
|
|
US7465703B1
|
|
Methods and kits useful for guiding osteoporosis related therapy
|
|
WO2004031727A2
|
|
Methods for diagnosing bone turnover disease
|
|
US7459276B2
|
|
Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
|
|
AU2003256816A1
|
|
Reagent and method for determination of a substance using an immunoaggregator
|
|
US7820393B2
|
|
Methods, kits and antibodies for detecting parathyroid hormone
|
|
EP1575507A2
|
|
Methods and devices for treating severe peripheral bacterial infections
|
|
US7056655B2
|
|
Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
|
|
EP1534309A2
|
|
Parathyroid hormone antagonists and uses thereof
|
|
WO2004028444A2
|
|
Parathyroid hormone antagonists and uses thereof
|
|
US2002160945A1
|
|
Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
|
|
WO9937798A1
|
|
Methods for detecting false negative results in blood screening assays using a single aliquot elevated baseline as an internal assay control
|
|
US6689566B1
|
|
Methods, kits, and antibodies for detecting parathyroid hormone
|
